WORCESTER, Mass., June 12, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it intends to complete a registered direct offering of up to 17,200,000 shares of its common stock to accredited investors on Monday, June 15, 2009. The per share price will be $0.6389. In addition, the Company will provide 50% warrant coverage, exercisable beginning 183 days following the closing date for a period ending on the fifth anniversary of the initial exercise date, with an exercise price of $0.76 per share.
